Medical Doctor Program year 2022 Reported 2020–2022 Source: CMS Open Payments, 2026 publication

Brittany Yee

Dermatology San Diego, CA Medical Doctor

NPI 1972990125 CMS profile 8806960

200 W Arbor Dr, #8425, San Diego, CA 92103

Open in the dashboard

General payments

$4,022

65 records reported · program years 2020–2022

Research payments

$0

Paid to them · None reported · program years 2020–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Brittany Yee of San Diego, CA is reported in the CMS Open Payments database as having received $4,022 across 65 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $494 22
2021 General $3,401 40
2020 General $126 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Yee
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Brittany Yee were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Brittany Yee Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $126 $235 $81–$756 $114
2021 $3,401 $377 $108–$1,108 $132
2022 $494 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2020–2022
  1. Pfizer Inc. $2,846 8 payments
  2. Janssen Biotech, Inc. $247 17 payments
  3. VYNE Pharmaceuticals Inc. $206 5 payments
  4. Regeneron Healthcare Solutions, Inc. $114 4 payments
  5. Sun Pharmaceutical Industries Inc. $92 5 payments
  6. AbbVie, Inc. $70 3 payments
  7. Almirall LLC $69 3 payments
  8. Sanofi-Aventis U.S. LLC $63 3 payments
  9. LEO Pharma Inc. $62 3 payments
  10. Incyte Corporation $54 3 payments
  11. Other $199 11 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,700 1 payment
  2. Food and Beverage $1,223 63 payments
  3. Education $99 1 payment
Products named General payments · program years 2020–2022
  1. TREMFYA $228 16 payments
  2. EUCRISA $119 6 payments
  3. SIMPONI ARIA $118 2 payments
  4. STELARA $118 2 payments
  5. DUPIXENT Inflammation And Immunology $114 4 payments
  6. DUPIXENT Immunology $108 5 payments
  7. AMZEEQ $106 2 payments
  8. ZILXI $100 3 payments
  9. RINVOQ $68 3 payments
  10. ILUMYA $57 3 payments
  11. Other $550 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

2,244

Median for Dermatology: 534

Drug cost

$369,672

Median for Dermatology: $67,151

Branded share of claims

19.5%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 39 $232,833
Dupixent Pen Dupilumab Brand 12 $43,624
Amjevita(Cf) Autoinjector Adalimumab-Atto Brand 17 $21,776
Fluorouracil Generic 330 $12,048
Vectical Calcitriol Brand 76 $11,620
Pimecrolimus Generic 47 $5,484
Triamcinolone Acetonide Generic 263 $5,441
Tacrolimus Generic 53 $4,179
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 203 $4,083
Ketoconazole Generic 244 $3,568

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$2,044

Medicare's payments for the services billed

Medicare patients

15

Average age 60

Services billed

53

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

65 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record